Related Experiment Video
Updated: Aug 23, 2026
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
Multiple sclerosis in children
1Service de Neurologie Pédiatrique and INSERM E0109, Hôpital Bicêtre, Faculte de Medecine Paris-Sud, 94276 Le Kremlin Bicetre, Cedex, France. marc.tardieu@kb.u-psud.fr
Insights
Pediatric multiple sclerosis (MS) diagnosis is challenging, especially in children under 10. Factors like younger age and polysymptomatic presentation may indicate a lower MS risk, with outcomes potentially better than in adults.
Area of Science:
- Pediatric Neurology
- Neuroimmunology
- Demyelinating Diseases
Background:
- Multiple sclerosis (MS) can manifest in childhood, presenting diagnostic challenges.
- Initial demyelinating events in children may mimic other conditions like acute disseminated encephalomyelitis or CNS vasculitis.
- Early diagnosis is crucial for appropriate management and understanding disease trajectory.
Purpose of the Study:
- To review the diagnostic challenges of pediatric multiple sclerosis (MS).
- To identify factors influencing the risk of developing MS in children.
- To discuss the prognosis and treatment considerations for MS in pediatric populations.
Main Methods:
- Review of existing literature on pediatric multiple sclerosis.
- Analysis of clinical presentation and diagnostic criteria for childhood MS.
- Evaluation of prognostic indicators and treatment outcomes in pediatric MS cases.
Main Results:
- The risk of developing MS in children is lower with younger age (<10 years), altered consciousness, polysymptomatic presentation, and large white matter lesions.
- Pediatric MS may have a slightly better prognosis compared to adult-onset MS.
- Methylprednisolone is the primary initial treatment; data on beta-interferon efficacy in children is limited.
Conclusions:
- Diagnosing MS in children requires careful consideration of differential diagnoses.
- Certain clinical and radiological features can help stratify MS risk in pediatric patients.
- Further research is needed on long-term treatment outcomes, particularly for disease-modifying therapies like beta-interferon, in children with MS.
Abstract:
Multiple sclerosis can develop during childhood, even among children under 10 years of age, and the initial diagnosis can be difficult. A first demyelinating event in children may be an episode of monophasic acute disseminated encephalomyelitis or a first episode of a macrophage activation syndrome, angiitis affecting the central nervous system or MS. The risk of developing MS is lower if: the child is younger than 10 years old; onset is associated with severely altered consciousness; presentation is polysymptomatic; or there are large and poorly limited lesions of the white matter. MS in children probably has a slightly better outcome than MS in adults. Initial treatment mainly relies on methylprednisolone, and there is little information on the results of beta interferon treatment in children with MS.
